Benzinga  9 hrs ago  Comment 
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Proceedings of the National Academy of Sciences (PNAS) has published a paper demonstrating that the Company's proprietary VelociGene® and VelocImmune® technologies enabled...
newratings.com  Jun 26  Comment 
LEVERKUSEN (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA (aflibercept) Injection by the Ministry of Health, Labour and Welfare or...
Jutia Group  Jun 25  Comment 
[PR Newswire] - TARRYTOWN, N.Y., June 25, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the third annual Regeneron Prize for Creative Innovation, an award designed to acknowledge, reward and...
Market Intelligence Center  Jun 22  Comment 
The option-trade picking algorithms behind MarketIntelligenceCenter.com's Artifical Intelligence Center have selected a covered-call trade on Regeneron Pharmaceuticals Inc (REGN) that includes 5.34% downside protection. Sell one contract of the...
Benzinga  Jun 10  Comment 
Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show. Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares were trading lower by $16 (3 percent) at $510.09 on Wednesday. The sharp decline is taking place...
Motley Fool  Jun 10  Comment 
A key advisory committee has given Regeneron Pharmaceuticals Inc.'s Praluent the thumbs up.
Benzinga  Jun 10  Comment 
A key regulatory advisory panel recommended approval of a cholesterol treatment under joint development by Sanofi SA (ADR) (NYSE: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN), the companies said Wednesday. A final ruling is expected...
Forbes  Jun 10  Comment 
In early trading on Wednesday, shares of Netflix (NFLX) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.7%. Year to date, Netflix registers a 96.5% gain.
Benzinga  Jun 10  Comment 
Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 11.32 percent to $89.15 in pre-market after falling 0.24 percent on Tuesday. Francesca's Holdings Corp (NASDAQ: FRAN) shares fell 5.16 percent to $15.25 in pre-market trading....
Benzinga  Jun 10  Comment 
newratings.com  Jun 9  Comment 
WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc (REGN) and Sanofi (SNY) on Tuesday said a panel of the U.S. Food and Drug Administration recommended the approval of the investigational therapy Praluent (alirocumab) Injection. The FDA's...


Since its inception in 1988, Regeneron Pharmaceuticals, Inc. (REGN) has operated as a research and development (R&D) company engaged in the development of drugs for the treatment of various diseases. Regeneron's goal is to become a fully integrated biopharmaceutical company by commercializing these drugs. The company has advanced a few of its pipeline drugs into clinical stage development. The leading drug programs in this regard are IL-1, for inflamatory disease, and VEGF, for cancer and eye diseases. Revenues consist of R&D collaboration payments from development partner Sanofi-Aventis and contract manufacturing payments from pharmaceutical giant Merck for a pediatric vaccine. Manufacturing agreement expired in October 2006. From 2007, revenue will mainly derive from collaboration with Sanofi-Aventis and Bayer and from technology transfers.

Regeneron is cururently based in Tarrytown, NY. In December 2006, the company signed a 15-year lease with BioMed Realty Trust, Inc. for a new corporate headquarters and research and development complex to be constructed adjacent to its current facility at the Landmark at Eastview in the Town of Greenburgh in Westchester County, New York. Regeneron also has the option to extend the lease for three additional 5-year periods. The new facilities will be constructed by BioMed Realty Trust over the next two years.

The Platform Techonology

Regeneron's most important propriatary technology is Trap Technology utilizing engineered antibody techniques. The decoy receptors (Traps) are composed of fusions between two distinct receptor components and a portion of an antibody molecule called the "Fc region", resulting in the generation of blockers with markedly increased affinity over that offered by single component reagents. Regeneron has applied this proprietary Trap technology to create a number of therapeutic candidates such as the IL-1 Trap and the VEGF Trap. The company also developed Velocigene/VelocImmune Technology which allows custom and precise manipulation of very large sequences of DNA to produce a highly customized knock-out of a specified target gene and accelerates the production of knock-out and transgenic expression models without using either positive/negative selection or isogenic DNA.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki